BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003;63:535-53. [PMID: 12656652 DOI: 10.2165/00003495-200363060-00002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Salem A, Khanfar E, Nagy S, Széchenyi A. Cocrystals of tuberculosis antibiotics: Challenges and missed opportunities. Int J Pharm 2022;623:121924. [PMID: 35738333 DOI: 10.1016/j.ijpharm.2022.121924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gao LJ, Huang ZH, Jin QY, Zhang GY, Gao MX, Qian JY, Zhu SX, Yu Y. Delayed diagnosis and comprehensive treatment of cutaneous tuberculosis: A case report. World J Clin Cases 2021; 9(16): 4007-4015 [PMID: 34141760 DOI: 10.12998/wjcc.v9.i16.4007] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Batisai E. Multicomponent crystals of anti-tuberculosis drugs: a mini-review. RSC Adv 2020;10:37134-41. [PMID: 35521272 DOI: 10.1039/d0ra06478e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Luciani-Giacobbe LC, Lorenzutti AM, Litterio NJ, Ramírez-Rigo MV, Olivera ME. Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. Drug Deliv Transl Res 2021;11:894-908. [PMID: 32901368 DOI: 10.1007/s13346-020-00847-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Meirelles L, Carazo E, Borrego-sánchez A, Barbosa R, Moura T, Aguzzi C, Sainz-diaz C, Viseras C, Raffin F. Design and characterization of a tuberculostatic hybrid based on interaction of ethambutol with a raw palygorskite. Applied Clay Science 2019;181:105213. [DOI: 10.1016/j.clay.2019.105213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Nagarajan S, Whitaker P. Management of adverse reactions to first-line tuberculosis antibiotics. Curr Opin Allergy Clin Immunol 2018;18:333-41. [PMID: 29901473 DOI: 10.1097/ACI.0000000000000462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
7 Al-Shaer MH, Elewa H, Alkabab Y, Nazer LH, Heysell SK. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. BMC Infect Dis 2018;18:384. [PMID: 30089476 DOI: 10.1186/s12879-018-3309-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Shams T, Parhizkar M, Illangakoon U, Orlu M, Edirisinghe M. Core/shell microencapsulation of indomethacin/paracetamol by co-axial electrohydrodynamic atomization. Materials & Design 2017;136:204-13. [DOI: 10.1016/j.matdes.2017.09.052] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
9 Guo N, Hou B, Wang N, Xiao Y, Huang J, Guo Y, Zong S, Hao H. In Situ Monitoring and Modeling of the Solution-Mediated Polymorphic Transformation of Rifampicin: From Form II to Form I. J Pharm Sci 2018;107:344-52. [PMID: 29031974 DOI: 10.1016/j.xphs.2017.10.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
10 Silva VDD, Mello FCQ, Figueiredo SCA. Estimated rates of recurrence, cure, and treatment abandonment in patients with pulmonary tuberculosis treated with a -four-drug fixed-dose combination regimen at a tertiary health care facility in the city of Rio de Janeiro, Brazil. J Bras Pneumol 2017;43:113-20. [PMID: 28538778 DOI: 10.1590/S1806-37562016000000204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Dilrukshi MDSA, Ratnayake CAP, Gnanathasan CA. Oral pyridoxine can substitute for intravenous pyridoxine in managing patients with severe poisoning with isoniazid and rifampicin fixed dose combination tablets: a case report. BMC Res Notes 2017;10:370. [PMID: 28789699 DOI: 10.1186/s13104-017-2678-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 Al-Shaer MH, Mansour H, Elewa H, Salameh P, Iqbal F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infect Dis 2017;17:118. [PMID: 28152986 DOI: 10.1186/s12879-017-2231-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lima GC, Silva EV, Magalhães PO, Naves JS. Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Braz J Microbiol 2017;48:198-207. [PMID: 28063922 DOI: 10.1016/j.bjm.2016.12.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
14 Agertt VA, Bonez PC, Mizdal CR, Rossi GG, Flores VDC, Campos MMAD. In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis. Braz J Pharm Sci 2016;52:575-80. [DOI: 10.1590/s1984-82502016000300022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T, Ezechi OC, Yimer G, Yamuah LK, Medhin G, Connolly C, Rida W, Aderaye G, Zumla AI, Onyebujoh PC; 4FDC Study Group. Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial. PLoS One 2016;11:e0157434. [PMID: 27322164 DOI: 10.1371/journal.pone.0157434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
16 Javad Nasiri M, Chirani AS, Amin M, Halabian R, Imani Fooladi AA. Isoniazid-resistant tuberculosis in Iran: A systematic review. Tuberculosis (Edinb) 2016;98:104-9. [PMID: 27156625 DOI: 10.1016/j.tube.2016.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Wu JT, Chiu CT, Wei YF, Lai YF. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinics (Sao Paulo) 2015;70:429-34. [PMID: 26106962 DOI: 10.6061/clinics/2015(06)08] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
18 Monedero I, Caminero JA. MDR-/XDR-TB management: what it was, current standards and what is ahead. Expert Review of Respiratory Medicine 2014;3:133-45. [DOI: 10.1586/ers.09.6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
19 Choonara YE, Pillay V, Ndesendo VM, du Toit LC, Kumar P, Khan RA, Murphy CS, Jarvis D. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. Colloids and Surfaces B: Biointerfaces 2011;87:243-54. [DOI: 10.1016/j.colsurfb.2011.05.025] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
20 Mustafa AA, Kowalski SR. A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines. Libyan J Med 2010;5. [PMID: 21483564 DOI: 10.3402/ljm.v5i0.5403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Eisenberg DM, Harris ES, Littlefield BA, Cao S, Craycroft JA, Scholten R, Bayliss P, Fu Y, Wang W, Qiao Y, Zhao Z, Chen H, Liu Y, Kaptchuk T, Hahn WC, Wang X, Roberts T, Shamu CE, Clardy J. Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 2011;82:17-33. [PMID: 21108995 DOI: 10.1016/j.fitote.2010.11.017] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
22 Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, Machado Junior A, Lemos AC, Netto AR, Durovni B, Sant'Anna CC, Lima D, Capone D, Barreira D, Matos ED, Mello FC, David FC, Marsico G, Afiune JB, Silva JR, Jamal LF, Telles MA, Hirata MH, Dalcolmo MP, Rabahi MF, Cailleaux-Cesar M, Palaci M, Morrone N, Guerra RL, Dietze R, Miranda SS, Cavalcante SC, Nogueira SA, Nonato TS, Martire T, Galesi VM, Dettoni Vdo V; BTA Committee on Tuberculosis., BTA Guidelines on Tuberculosis Work Group. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol 2009;35:1018-48. [PMID: 19918635 DOI: 10.1590/s1806-37132009001000011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 134] [Article Influence: 7.1] [Reference Citation Analysis]
23 Cooppan S, Pillay V, Choonara YE, Toit LCD, Ndesendo VM. Rationalising fixed dose combinations for tuberculosis and acquired immunodeficiency syndrome therapy. IJBT 2010;11:284. [DOI: 10.1504/ijbt.2010.036601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Mishra LC, Bhattacharya A, Bhasin VK. Phytochemical licochalcone A enhances antimalarial activity of artemisinin in vitro. Acta Trop 2009;109:194-8. [PMID: 19063856 DOI: 10.1016/j.actatropica.2008.11.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
25 Ashokraj Y, Kaur KJ, Singh I, Kohli G, Bhade SR, Varma M, Agrawal S, Panchagnula R. In Vivo Dissolution: Predominant Factor Affecting the Bioavailability of Rifampicin in its Solid Oral Dosage Forms. Clinical Research and Regulatory Affairs 2008;25:1-12. [DOI: 10.1080/10601330701885041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
26 Hiremath PS, Saha RN. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: Design and in vitro evaluations. International Journal of Pharmaceutics 2008;362:118-25. [DOI: 10.1016/j.ijpharm.2008.06.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
27 du Toit LC, Pillay V, Danckwerts MP, Penny C. Formulation and Statistical Optimization of a Novel Crosslinked Polymeric Anti‐Tuberculosis Drug Delivery System. Journal of Pharmaceutical Sciences 2008;97:2176-207. [DOI: 10.1002/jps.21159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci U S A 2007;104:19914-9. [PMID: 18056635 DOI: 10.1073/pnas.0707766104] [Cited by in Crossref: 140] [Cited by in F6Publishing: 143] [Article Influence: 8.8] [Reference Citation Analysis]
29 Domínguez-castellano Á, del Arco A, Canueto-quintero J, Rivero-román A, María Kindelán J, Creagh R, Díez-garcía F. Guía de práctica clínica de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI) sobre el tratamiento de la tuberculosis. Enfermedades Infecciosas y Microbiología Clínica 2007;25:519-34. [DOI: 10.1157/13109989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
30 Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol 2007;3:360-6. [PMID: 17576417 DOI: 10.1038/nchembio0707-360] [Cited by in Crossref: 222] [Cited by in F6Publishing: 234] [Article Influence: 13.9] [Reference Citation Analysis]
31 Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006;66:2299-308. [PMID: 17181373 DOI: 10.2165/00003495-200666180-00003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
32 Albertini M. Traitement de la tuberculose. Archives de Pédiatrie 2005;12:S110-6. [DOI: 10.1016/s0929-693x(05)80025-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-75. [PMID: 15823770 DOI: 10.1016/j.clinthera.2004.12.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 3.3] [Reference Citation Analysis]
34 Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. International Journal of Pharmaceutics 2004;287:97-112. [DOI: 10.1016/j.ijpharm.2004.09.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
35 Mwinga A, Bernard Fourie P. Prospects for new tuberculosis treatment in Africa. Trop Med Int Health 2004;9:827-32. [PMID: 15228494 DOI: 10.1111/j.1365-3156.2004.01274.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
36 Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. International Journal of Pharmaceutics 2004;276:41-9. [DOI: 10.1016/j.ijpharm.2004.02.019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]